[go: up one dir, main page]

WO2002036066A3 - Compositions pharmaceutiques comprenant des complexes de vanadium organiques pour le traitement de l'ischemie - Google Patents

Compositions pharmaceutiques comprenant des complexes de vanadium organiques pour le traitement de l'ischemie Download PDF

Info

Publication number
WO2002036066A3
WO2002036066A3 PCT/IL2001/001004 IL0101004W WO0236066A3 WO 2002036066 A3 WO2002036066 A3 WO 2002036066A3 IL 0101004 W IL0101004 W IL 0101004W WO 0236066 A3 WO0236066 A3 WO 0236066A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
ischemia
pharmaceutical compositions
vanadium
oxovanadium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2001/001004
Other languages
English (en)
Other versions
WO2002036066A2 (fr
Inventor
Yoram Shechter
Matityahu Fridkin
Itzhak Goldwaser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13939900A external-priority patent/IL139399A0/xx
Priority claimed from IL14118201A external-priority patent/IL141182A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to AU2002214222A priority Critical patent/AU2002214222A1/en
Publication of WO2002036066A2 publication Critical patent/WO2002036066A2/fr
Publication of WO2002036066A3 publication Critical patent/WO2002036066A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des complexes de vanadium organiques peuvent être utilisés dans la prévention et/ou le traitement de l'ischémie cérébrale. Le complexe de vanadium peut être du bis(N-octyl cystéine amide) oxovanadium (IV), bis(maltolato)oxovanadium (IV), bis(picolinato) oxovanadium (IV) ou un complexe de vanadium d'un hydroxamate, de préférence un monohydroxamate, et est de préférence également un complexe de vanadium d'un monohydroxamate de formule R-CO-NHOH.X, où R représente un radical sélectionné parmi: (i) H2N-CH(COY)-(CH2)n-; (ii) H2N-CH(COOH)-CH2-S-CH2-; et (iii) pyridyle, pipéridyle ou tétrahydro-isoquinolinyle, où n représente 1, 2 ou 3, et Y représente OH ou NH2; et X est un composé de vanadium sélectionné parmi un sel de vanadyle (VO2+), de métavanadate (VO¿3?-) ou de vanadate (VO¿4?3-).
PCT/IL2001/001004 2000-11-01 2001-10-30 Compositions pharmaceutiques comprenant des complexes de vanadium organiques pour le traitement de l'ischemie Ceased WO2002036066A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002214222A AU2002214222A1 (en) 2000-11-01 2001-10-30 Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL139399 2000-11-01
IL13939900A IL139399A0 (en) 2000-11-01 2000-11-01 Pharmaceutical compositions comprising vanadium complexes of hydroxamates
IL14118201A IL141182A0 (en) 2001-01-30 2001-01-30 Pharmaceutical compositions comprising organic vanadium complexes
IL141182 2001-01-30

Publications (2)

Publication Number Publication Date
WO2002036066A2 WO2002036066A2 (fr) 2002-05-10
WO2002036066A3 true WO2002036066A3 (fr) 2002-08-01

Family

ID=26323987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/001004 Ceased WO2002036066A2 (fr) 2000-11-01 2001-10-30 Compositions pharmaceutiques comprenant des complexes de vanadium organiques pour le traitement de l'ischemie

Country Status (2)

Country Link
AU (1) AU2002214222A1 (fr)
WO (1) WO2002036066A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3292116T3 (pl) 2015-02-02 2022-02-21 Valo Health, Inc. 3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
WO2016126726A1 (fr) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Acides hydroxamiques bicycliques [4,6,0] en tant qu'inhibiteurs hdac6
WO2017218950A1 (fr) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. Indanes d'acide hydroxamique 2-spiro-5 et 6 utilisés en tant qu'inhibiteurs de hdac
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039385A1 (fr) * 1995-06-06 1996-12-12 Pfizer Inc. (indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1999012875A1 (fr) * 1997-09-11 1999-03-18 Yeda Research And Development Co. Ltd. Complexes de vanadium de monohydroxamates et compositions pharmaceutiques les renfermant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039385A1 (fr) * 1995-06-06 1996-12-12 Pfizer Inc. (indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1999012875A1 (fr) * 1997-09-11 1999-03-18 Yeda Research And Development Co. Ltd. Complexes de vanadium de monohydroxamates et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
WO2002036066A2 (fr) 2002-05-10
AU2002214222A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
EP0662830B1 (fr) CHELATES DE VITAMINES AROMATIQUES A LIAISON (pi)
ATE320806T1 (de) Zink-aminosäure-chelate mit glyzin und einer schwefelhaltigen aminosäure als liganden
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ATE523194T1 (de) Bis(thiohydrazidamide) in kombination mit taxol für die behandlung von krebs
ATE389400T1 (de) Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
BR9904998A (pt) Derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico
CA2230140A1 (fr) Lutte contre les champignons nocifs au moyen d'une combinaison d'une substance active inhibant la respiration par l'intermediaire du complexe de cytochrome iii, et d'un amide
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
CA2121523A1 (fr) Derives de sulfonamide
DE69424986D1 (de) Spülmittelzusammensetzungen
ATE128707T1 (de) Quinoloncarbonsäurederivat.
ES2112329T3 (es) Composiciones de vanadio.
MX2015004435A (es) Composiciones biocidas que comprenden quelantes de hierro.
WO2002036066A3 (fr) Compositions pharmaceutiques comprenant des complexes de vanadium organiques pour le traitement de l'ischemie
EA199800998A3 (ru) Хелатные соединения металлов с макроциклическими полиаминокарбоновыми соединениями и их использование для диагностических исследований
EP0541802A4 (en) Diphenylmethylpiperazine derivative
WO1998046576A3 (fr) Promedicaments haloalcoxycarbonyles
ATE153664T1 (de) Imidazoacridine und ihre antineoplastische anwendung
WO2004085497A3 (fr) Composition catalytique
WO1994008949A3 (fr) Chelates de metal-oxime utilises comme agents radiopharmaceutiques
BR9812640A (pt) Complexos de monoidroxamatos de vanádio e composições farmacêuticas compreendendo os mesmos
IL104972A0 (en) Beta-amino acid derivatives,their production and pharmaceutical compositions containing them
GR3021143T3 (en) Imidazole derivatives and pharmaceutical compositions containing the same.
Dessì et al. EPR investigation of the oxovanadium (IV) complexes formed by the tripeptide glutathione and some related ligands in aqueous solution
GR3029428T3 (en) Novel bisoxadiazolidine derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP